Efficacy News and Research

RSS

Haemodynamic variables may distinguish pre- from post-capillary PH

Researchers have identified the haemodynamic variables that best distinguish between patients with idiopathic pulmonary arterial hypertension and isolated post-capillary pulmonary hypertension.

16 Nov 2015

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Tyrogenex, a privately held company focused on the development of targeted therapeutics for cancer and ophthalmology, today announced data from its phase 1 open-label study of orally-administered X-82 in patients for wet age-related macular degeneration (AMD).

15 Nov 2015

Adynovate approved for patients with Hemophilia A

The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.

15 Nov 2015

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now approved for patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has gotten worse after treatment with other EGFR-blocking therapy.

14 Nov 2015

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats.

13 Nov 2015

New study refutes increased cancer risk for patients undergoing spinal fusion surgery with rhBMP

A new study may alleviate concerns regarding increased cancer risk for patients undergoing spinal fusion surgery with recombinant human bone morphogenetic protein (rhBMP). The study appears in November 15 issue of Spine, published by Wolters Kluwer.

13 Nov 2015

MD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patients

A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth.

12 Nov 2015

Intravenous PEG-asparaginase use recommended in paediatric ALL

Phase III trial results support the use of intravenously administered PEGylated Escherichia coli asparaginase as the preparation of choice in children and adolescents with acute lymphoblastic leukaemia.

11 Nov 2015

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

A drug approved to treat rheumatoid arthritis, tocilizumab (Actemra, Genentech), is a potential new therapy for patients with polymyalgia rheumatica, according to an open-label, phase II study presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on November 10.

11 Nov 2015

Study shows mindfulness meditation reduces pain more effectively than placebo

Scientists at Wake Forest Baptist Medical Center have found new evidence that mindfulness meditation reduces pain more effectively than placebo.

11 Nov 2015

Betalin launches new EMP technology that could transform diabetes treatment

Betalin Therapeutics, a biotech company specializing in tissue engineering for curing diabetes, introduces the Engineered Micro Pancreas (EMP), a novel technology that provides significant levels of glucose-regulated insulin secretion over extended periods of time.

11 Nov 2015

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.

11 Nov 2015

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Data presented yesterday by researchers for Mallinckrodt plc, a leading specialty biopharmaceutical company, suggest that H.P. Acthar® Gel (repository corticotropin injection) reduces certain measures of disease activity in patients with persistently active Systemic Lupus Erythematosus (SLE) who are receiving corticosteroid therapy.

10 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

Innovative high school health program helps students maintain healthier weights, alleviate depression

An innovative high school health program helped students maintain healthier weights and even alleviated severe depression for a full year after the program ended.

10 Nov 2015

Public policy needed to reduce stem cell tourism, say experts

The continued marketing and use of experimental stem cell-based interventions inside and outside the United States is problematic and unsustainable, according to a new paper by science policy and bioethics experts at Rice University's Baker Institute for Public Policy and Wake Forest University.

10 Nov 2015

PAREXEL expands market access and clinical evidence services

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced expanded evidence-based services for biopharmaceutical products.

10 Nov 2015

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Although there are anecdotal reports indicating that cannabinoids, especially marijuana (or herbal cannabis), may be of therapeutic benefit for some patients with rheumatic complaints, a new review published in Arthritis Care & Research, a journal of the American College of Rheumatology, finds scant scientific evidence supporting any use of cannabinoids in rheumatic diseases. Furthermore, not a single controlled study has examined herbal cannabis in the rheumatology patient population.

10 Nov 2015

Efficacy News and Research

Haemodynamic variables may distinguish pre- from post-capillary PH

Tyrogenex announces results from phase 1 study of orally-administered X-82 in patients with AMD

Adynovate approved for patients with Hemophilia A

FDA grants accelerated approval for Tagrisso to treat patients with advanced NSCLC

Analyzing potential TB vaccine

New study refutes increased cancer risk for patients undergoing spinal fusion surgery with rhBMP

MD Anderson study reveals why chemotherapy drugs not effective for many pancreatic cancer patients

Intravenous PEG-asparaginase use recommended in paediatric ALL

Tocilizumab drug offers potential treatment for patients with polymyalgia rheumatics

Study shows mindfulness meditation reduces pain more effectively than placebo

Betalin launches new EMP technology that could transform diabetes treatment

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Innovative high school health program helps students maintain healthier weights, alleviate depression

Public policy needed to reduce stem cell tourism, say experts

PAREXEL expands market access and clinical evidence services

New review finds scant scientific evidence supporting use of cannabinoids in rheumatic diseases

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News